nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—ADRA1B—polycystic ovary syndrome	0.951	1	CbGaD
Lisdexamfetamine—ADRA1B—Adrenoceptors—ADRA1D—polycystic ovary syndrome	0.00296	0.0683	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Adrenoceptors—ADRA1A—polycystic ovary syndrome	0.00218	0.0504	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Adrenoceptors—ADRB3—polycystic ovary syndrome	0.0021	0.0485	CbGpPWpGaD
Lisdexamfetamine—Labetalol—ADRB3—polycystic ovary syndrome	0.00139	0.254	CrCbGaD
Lisdexamfetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—TH—polycystic ovary syndrome	0.00126	0.0291	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Adrenoceptors—ADRB2—polycystic ovary syndrome	0.00113	0.0262	CbGpPWpGaD
Lisdexamfetamine—L-Phenylalanine—TH—polycystic ovary syndrome	0.0011	0.2	CrCbGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—ADIPOR1—polycystic ovary syndrome	0.00107	0.0248	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—ADIPOR2—polycystic ovary syndrome	0.00107	0.0248	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—ADRA1D—polycystic ovary syndrome	0.00105	0.0242	CbGpPWpGaD
Lisdexamfetamine—Dextroamphetamine—ADRA1B—polycystic ovary syndrome	0.000993	0.181	CrCbGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—TH—polycystic ovary syndrome	0.000948	0.0219	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—ADRA1D—polycystic ovary syndrome	0.00088	0.0203	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—CCNE2—polycystic ovary syndrome	0.000866	0.02	CbGpPWpGaD
Lisdexamfetamine—Lisinopril—ACE—polycystic ovary syndrome	0.000801	0.146	CrCbGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—ADRA1A—polycystic ovary syndrome	0.000772	0.0178	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—ADRB3—polycystic ovary syndrome	0.000743	0.0171	CbGpPWpGaD
Lisdexamfetamine—Dextroamphetamine—ADRA1A—polycystic ovary syndrome	0.000668	0.122	CrCbGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—ADRA1A—polycystic ovary syndrome	0.000649	0.015	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—PLEKHG5—polycystic ovary syndrome	0.000648	0.0149	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—ADRB3—polycystic ovary syndrome	0.000625	0.0144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—INS-IGF2—polycystic ovary syndrome	0.000617	0.0142	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TH—polycystic ovary syndrome	0.000606	0.014	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—TH—polycystic ovary syndrome	0.000565	0.013	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Alpha-synuclein signaling—TH—polycystic ovary syndrome	0.00055	0.0127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—ADRA1D—polycystic ovary syndrome	0.000543	0.0125	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TH—polycystic ovary syndrome	0.000536	0.0124	CbGpPWpGaD
Lisdexamfetamine—Labetalol—ADRB2—polycystic ovary syndrome	0.00053	0.0966	CrCbGaD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—TH—polycystic ovary syndrome	0.000468	0.0108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—ADRA1A—polycystic ovary syndrome	0.000428	0.00987	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—ADRB2—polycystic ovary syndrome	0.000401	0.00926	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—ADRA1A—polycystic ovary syndrome	0.0004	0.00924	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCB6—polycystic ovary syndrome	0.000364	0.0084	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A4—polycystic ovary syndrome	0.00036	0.00832	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—GAB1—polycystic ovary syndrome	0.000347	0.008	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—ADRB2—polycystic ovary syndrome	0.000337	0.00778	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRA1D—polycystic ovary syndrome	0.000314	0.00723	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—INSR—polycystic ovary syndrome	0.000312	0.0072	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PTAFR—polycystic ovary syndrome	0.000269	0.00621	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—ADRA1D—polycystic ovary syndrome	0.000261	0.00603	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—ADIPOQ—polycystic ovary syndrome	0.00026	0.006	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—CCNB1—polycystic ovary syndrome	0.00026	0.006	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.000259	0.00598	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—SLC2A4—polycystic ovary syndrome	0.000246	0.00567	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCB6—polycystic ovary syndrome	0.000245	0.00565	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—CAMK2D—polycystic ovary syndrome	0.000244	0.00563	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A4—polycystic ovary syndrome	0.000243	0.0056	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PTAFR—polycystic ovary syndrome	0.000241	0.00556	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.000235	0.00541	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1D—polycystic ovary syndrome	0.000234	0.00539	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRA1A—polycystic ovary syndrome	0.000231	0.00533	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—NPB—polycystic ovary syndrome	0.000228	0.00527	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—PTGER3—polycystic ovary syndrome	0.000223	0.00513	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—LHCGR—polycystic ovary syndrome	0.000223	0.00513	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB3—polycystic ovary syndrome	0.000223	0.00513	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCB6—polycystic ovary syndrome	0.000217	0.00501	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—DLG4—polycystic ovary syndrome	0.000216	0.00497	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC2A4—polycystic ovary syndrome	0.000215	0.00496	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—PTAFR—polycystic ovary syndrome	0.000208	0.0048	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRA1D—polycystic ovary syndrome	0.000202	0.00466	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—ADRA1A—polycystic ovary syndrome	0.000193	0.00445	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—PTGER3—polycystic ovary syndrome	0.000191	0.0044	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—LHCGR—polycystic ovary syndrome	0.000191	0.0044	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—CAMK2D—polycystic ovary syndrome	0.000187	0.00431	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—GNRH1—polycystic ovary syndrome	0.000179	0.00413	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—PTAFR—polycystic ovary syndrome	0.000178	0.00411	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC2A4—polycystic ovary syndrome	0.000175	0.00403	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.000175	0.00403	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—NPB—polycystic ovary syndrome	0.000174	0.00401	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA1D—polycystic ovary syndrome	0.000173	0.00399	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—ADRA1A—polycystic ovary syndrome	0.000172	0.00398	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—DLG4—polycystic ovary syndrome	0.000165	0.00381	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC2A4—polycystic ovary syndrome	0.000164	0.00378	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—FSHR—polycystic ovary syndrome	0.000163	0.00376	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—LEP—polycystic ovary syndrome	0.000162	0.00373	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—polycystic ovary syndrome	0.00016	0.0037	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—CAMK2D—polycystic ovary syndrome	0.00016	0.0037	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.000158	0.00364	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC2A4—polycystic ovary syndrome	0.000155	0.00357	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—TRPV6—polycystic ovary syndrome	0.000155	0.00357	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRA1A—polycystic ovary syndrome	0.000149	0.00344	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—CAMK2D—polycystic ovary syndrome	0.000145	0.00335	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PTGER3—polycystic ovary syndrome	0.000145	0.00335	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—LHCGR—polycystic ovary syndrome	0.000145	0.00335	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB3—polycystic ovary syndrome	0.000143	0.00331	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SCNN1A—polycystic ovary syndrome	0.00014	0.00323	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—FSHR—polycystic ovary syndrome	0.00014	0.00322	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—NRG1—polycystic ovary syndrome	0.000137	0.00317	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—PTAFR—polycystic ovary syndrome	0.000136	0.00313	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—AKT2—polycystic ovary syndrome	0.000133	0.00308	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRA1D—polycystic ovary syndrome	0.000132	0.00304	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—DLG4—polycystic ovary syndrome	0.000129	0.00297	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRA1A—polycystic ovary syndrome	0.000128	0.00294	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—MTNR1B—polycystic ovary syndrome	0.000127	0.00292	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB3—polycystic ovary syndrome	0.000123	0.00283	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—NRG1—polycystic ovary syndrome	0.000122	0.0028	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—LHB—polycystic ovary syndrome	0.000121	0.0028	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—GHRL—polycystic ovary syndrome	0.000121	0.00279	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB2—polycystic ovary syndrome	0.00012	0.00277	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—GNRH1—polycystic ovary syndrome	0.000119	0.00274	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—GNAS—polycystic ovary syndrome	0.000111	0.00257	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—CAMK2D—polycystic ovary syndrome	0.000111	0.00257	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC2A4—polycystic ovary syndrome	0.00011	0.00254	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—MTNR1B—polycystic ovary syndrome	0.000109	0.0025	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GHRL—polycystic ovary syndrome	0.000108	0.0025	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—FSHR—polycystic ovary syndrome	0.000106	0.00245	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—DLG4—polycystic ovary syndrome	9.85e-05	0.00227	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—NPB—polycystic ovary syndrome	9.83e-05	0.00227	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	9.79e-05	0.00226	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC2A4—polycystic ovary syndrome	9.76e-05	0.00225	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRA1A—polycystic ovary syndrome	9.72e-05	0.00224	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRB3—polycystic ovary syndrome	9.36e-05	0.00216	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—LHB—polycystic ovary syndrome	9.25e-05	0.00213	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	9.1e-05	0.0021	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GNRH1—polycystic ovary syndrome	9.04e-05	0.00208	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—NPB—polycystic ovary syndrome	8.93e-05	0.00206	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PLEKHG5—polycystic ovary syndrome	8.89e-05	0.00205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ARHGAP23—polycystic ovary syndrome	8.71e-05	0.00201	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ARHGAP30—polycystic ovary syndrome	8.71e-05	0.00201	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—SCT—polycystic ovary syndrome	8.66e-05	0.002	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	8.32e-05	0.00192	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—MTNR1B—polycystic ovary syndrome	8.27e-05	0.00191	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PTGER3—polycystic ovary syndrome	8.21e-05	0.00189	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—LHCGR—polycystic ovary syndrome	8.21e-05	0.00189	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PLEKHG5—polycystic ovary syndrome	8.08e-05	0.00186	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—GHRL—polycystic ovary syndrome	8.02e-05	0.00185	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB2—polycystic ovary syndrome	7.75e-05	0.00179	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PTAFR—polycystic ovary syndrome	7.68e-05	0.00177	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTGER3—polycystic ovary syndrome	7.45e-05	0.00172	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—LHCGR—polycystic ovary syndrome	7.45e-05	0.00172	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	7.45e-05	0.00172	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	6.99e-05	0.00161	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PTAFR—polycystic ovary syndrome	6.97e-05	0.00161	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	6.77e-05	0.00156	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	6.64e-05	0.00153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	6.59e-05	0.00152	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	6.59e-05	0.00152	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	6.12e-05	0.00141	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GHRL—polycystic ovary syndrome	6.1e-05	0.00141	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FLT4—polycystic ovary syndrome	6.03e-05	0.00139	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—FSHR—polycystic ovary syndrome	6.01e-05	0.00139	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PDE3B—polycystic ovary syndrome	5.99e-05	0.00138	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—TFRC—polycystic ovary syndrome	5.84e-05	0.00135	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	5.6e-05	0.00129	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	5.49e-05	0.00127	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—FSHR—polycystic ovary syndrome	5.45e-05	0.00126	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—PLAT—polycystic ovary syndrome	5.43e-05	0.00125	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	5.29e-05	0.00122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NPB—polycystic ovary syndrome	5.27e-05	0.00122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—LHB—polycystic ovary syndrome	5.23e-05	0.00121	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	5.11e-05	0.00118	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRB2—polycystic ovary syndrome	5.05e-05	0.00117	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	4.99e-05	0.00115	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A4—polycystic ovary syndrome	4.96e-05	0.00114	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—SCT—polycystic ovary syndrome	4.9e-05	0.00113	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRB3—polycystic ovary syndrome	4.8e-05	0.00111	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	4.77e-05	0.0011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—LHB—polycystic ovary syndrome	4.75e-05	0.00109	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	4.7e-05	0.00108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—GNAS—polycystic ovary syndrome	4.69e-05	0.00108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	4.67e-05	0.00108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNRH1—polycystic ovary syndrome	4.64e-05	0.00107	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—SCT—polycystic ovary syndrome	4.45e-05	0.00103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTGER3—polycystic ovary syndrome	4.4e-05	0.00102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LHCGR—polycystic ovary syndrome	4.4e-05	0.00102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	4.24e-05	0.000979	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—GNAS—polycystic ovary syndrome	4.16e-05	0.000961	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	4.14e-05	0.000956	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTAFR—polycystic ovary syndrome	4.12e-05	0.00095	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRA1D—polycystic ovary syndrome	4e-05	0.000922	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—INHBB—polycystic ovary syndrome	3.79e-05	0.000874	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PDE3B—polycystic ovary syndrome	3.54e-05	0.000816	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GHRL—polycystic ovary syndrome	3.45e-05	0.000796	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FSHR—polycystic ovary syndrome	3.22e-05	0.000743	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—POMC—polycystic ovary syndrome	3.15e-05	0.000728	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GHRL—polycystic ovary syndrome	3.13e-05	0.000723	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RACGAP1—polycystic ovary syndrome	3.03e-05	0.000699	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRA1A—polycystic ovary syndrome	2.95e-05	0.00068	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FST—polycystic ovary syndrome	2.87e-05	0.000663	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	2.86e-05	0.000659	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRB3—polycystic ovary syndrome	2.84e-05	0.000654	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LHB—polycystic ovary syndrome	2.8e-05	0.000647	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNRH1—polycystic ovary syndrome	2.74e-05	0.000632	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKR1C1—polycystic ovary syndrome	2.65e-05	0.000612	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GNAS—polycystic ovary syndrome	2.65e-05	0.000611	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SCT—polycystic ovary syndrome	2.63e-05	0.000606	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRB2—polycystic ovary syndrome	2.59e-05	0.000598	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MTNR1B—polycystic ovary syndrome	2.51e-05	0.000578	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGF18—polycystic ovary syndrome	2.46e-05	0.000568	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RBP4—polycystic ovary syndrome	2.44e-05	0.000563	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	2.43e-05	0.000561	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GNAS—polycystic ovary syndrome	2.4e-05	0.000555	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—YAP1—polycystic ovary syndrome	2.28e-05	0.000526	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GAB1—polycystic ovary syndrome	2.25e-05	0.000519	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—INSR—polycystic ovary syndrome	2.15e-05	0.000496	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKR1C3—polycystic ovary syndrome	2.04e-05	0.000471	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TNRC6B—polycystic ovary syndrome	2.01e-05	0.000464	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PGR—polycystic ovary syndrome	1.99e-05	0.000459	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GHRL—polycystic ovary syndrome	1.85e-05	0.000427	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PLAT—polycystic ovary syndrome	1.85e-05	0.000427	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—POMC—polycystic ovary syndrome	1.78e-05	0.000411	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ATF1—polycystic ovary syndrome	1.77e-05	0.000407	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TCF7L2—polycystic ovary syndrome	1.72e-05	0.000397	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKT2—polycystic ovary syndrome	1.71e-05	0.000395	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NGFR—polycystic ovary syndrome	1.63e-05	0.000376	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—POMC—polycystic ovary syndrome	1.62e-05	0.000373	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRL—polycystic ovary syndrome	1.61e-05	0.000373	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKT2—polycystic ovary syndrome	1.56e-05	0.000359	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRB2—polycystic ovary syndrome	1.53e-05	0.000353	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GNAS—polycystic ovary syndrome	1.42e-05	0.000328	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NCOR1—polycystic ovary syndrome	1.35e-05	0.000312	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NRG1—polycystic ovary syndrome	1.33e-05	0.000306	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IRS2—polycystic ovary syndrome	1.14e-05	0.000262	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LEP—polycystic ovary syndrome	1.11e-05	0.000257	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IRS1—polycystic ovary syndrome	9.93e-06	0.000229	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—POMC—polycystic ovary syndrome	9.56e-06	0.000221	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—INS—polycystic ovary syndrome	9.51e-06	0.000219	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1—polycystic ovary syndrome	9.2e-06	0.000212	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKT2—polycystic ovary syndrome	9.19e-06	0.000212	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SERPINE1—polycystic ovary syndrome	8.74e-06	0.000202	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—polycystic ovary syndrome	7.04e-06	0.000162	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—polycystic ovary syndrome	6.01e-06	0.000139	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—polycystic ovary syndrome	4.16e-06	9.59e-05	CbGpPWpGaD
